Online, people often mention NAD+ in the same breath as retatrutide or tirzepatide. It sounds like a set combo. It is not.
These are different tools with different kinds of evidence. CoreVials NAD+, retatrutide, and tirzepatide are for lab research only, not personal treatment plans.
Meet the Players in Plain English
Tirzepatide is a medicine studied (and approved for certain uses) that acts on two gut-hormone pathways linked to blood sugar and appetite. Big human trials measured weight and diabetes markers.
Retatrutide is an investigational drug that hits three related pathways. A major Phase 2 obesity study was published in 2023. Larger Phase 3 work is ongoing. It is not a casual "stack ingredient."
NAD+ is a cell energy helper molecule. Human studies mostly test NMN or NR (building blocks), and results for hard health outcomes are mixed. Start here if needed: what is NAD+?
Why Do People Talk About Them Together?
Because both topics touch metabolism: energy use, body weight, and how cells handle fuel.
That is a fair reason to ask questions. It is not proof that taking them together works better, feels better, or is safer.
What the Big Drug Trials Did Not Test
Retatrutide and tirzepatide trials looked at things like weight change, blood sugar, waist size, and side effects.
They did not include an NAD+, NMN, or NR arm. So you cannot honestly say "the trial supports adding NAD+."
More reading: how these drugs compare in trials, retatrutide explained.
What Is Missing
- No major randomized trial proves NAD+ + tirzepatide is a better plan
- No major randomized trial proves NAD+ + retatrutide is a standard protocol
- You cannot add marketing claims on top of trial weight-loss numbers and call it science
Better Questions for Research
- What happens to cell energy markers when appetite-pathway signaling changes?
- Which tissues should be measured?
- How do you design a fair control group?
Worse questions: personal milligram charts from social media. We will not provide those.
Lab Basics
COA lookup · how to read a COA · storage · research compliance
Quick Questions
Is there an official NAD+ + retatrutide protocol? No.
Does tirzepatide "drain" NAD+? That is not a main finding from the big obesity and diabetes trials. Do not treat forum guesses as fact.
Can you recommend a personal stack? No.
References
- Jastreboff, A.M., et al. (2023). Retatrutide Phase 2 obesity trial. NEJM. Read the study
- Frias, J.P., et al. (2021). Tirzepatide vs semaglutide in type 2 diabetes (SURPASS-2). NEJM. Read the study
- Aronne, L.J., et al. Tirzepatide vs semaglutide for obesity (SURMOUNT-5). NEJM. Read the study
- Freeberg, K.A., et al. (2023). NAD+-boosting compounds in humans. Advances in Nutrition. PMC full text
- Endocrine Reviews (2023). NAD+ in aging biology. DOI: 10.1210/endrev/bnad019
